156 related articles for article (PubMed ID: 12673729)
1. Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study.
Sorensen K; Levitt GA; Bull C; Dorup I; Sullivan ID
Cancer; 2003 Apr; 97(8):1991-8. PubMed ID: 12673729
[TBL] [Abstract][Full Text] [Related]
2. Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity.
Sorensen K; Levitt G; Bull C; Chessells J; Sullivan I
J Clin Oncol; 1997 Jan; 15(1):61-8. PubMed ID: 8996125
[TBL] [Abstract][Full Text] [Related]
3. Cardiac function in Wilms' tumor survivors.
Sorensen K; Levitt G; Sebag-Montefiore D; Bull C; Sullivan I
J Clin Oncol; 1995 Jul; 13(7):1546-56. PubMed ID: 7602343
[TBL] [Abstract][Full Text] [Related]
4. Does anthracycline administration by infusion in children affect late cardiotoxicity?
Levitt GA; Dorup I; Sorensen K; Sullivan I
Br J Haematol; 2004 Feb; 124(4):463-8. PubMed ID: 14984495
[TBL] [Abstract][Full Text] [Related]
5. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia.
Nysom K; Holm K; Lipsitz SR; Mone SM; Colan SD; Orav EJ; Sallan SE; Olsen JH; Hertz H; Jacobsen JR; Lipshultz SE
J Clin Oncol; 1998 Feb; 16(2):545-50. PubMed ID: 9469339
[TBL] [Abstract][Full Text] [Related]
6. Detection of early anthracycline-induced cardiotoxicity in childhood cancer with dobutamine stress echocardiography.
Lenk MK; Zeybek C; Okutan V; Ozcan O; Gökçay E
Turk J Pediatr; 1998; 40(3):373-83. PubMed ID: 9763901
[TBL] [Abstract][Full Text] [Related]
7. Low-dose daunorubicin in induction treatment of childhood acute lymphoblastic leukemia: no long-term cardiac damage in a randomized study of the Dutch Childhood Leukemia Study Group.
Rammeloo LA; Postma A; Sobotka-Plojhar MA; Bink-Boelkens MT; Berg A; Veerman AJ; Kamps WA
Med Pediatr Oncol; 2000 Jul; 35(1):13-9. PubMed ID: 10881002
[TBL] [Abstract][Full Text] [Related]
8. Late cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood.
Vandecruys E; Mondelaers V; De Wolf D; Benoit Y; Suys B
J Cancer Surviv; 2012 Mar; 6(1):95-101. PubMed ID: 21630046
[TBL] [Abstract][Full Text] [Related]
9. Subclinical cardiotoxicity in childhood cancer survivors exposed to very low dose anthracycline therapy.
Leger K; Slone T; Lemler M; Leonard D; Cochran C; Bowman WP; Bashore L; Winick N
Pediatr Blood Cancer; 2015 Jan; 62(1):123-7. PubMed ID: 25176022
[TBL] [Abstract][Full Text] [Related]
10. Late cardiac effects of anthracycline containing therapy for childhood acute lymphoblastic leukemia.
Rathe M; Carlsen NL; Oxhøj H
Pediatr Blood Cancer; 2007 Jun; 48(7):663-7. PubMed ID: 17405151
[TBL] [Abstract][Full Text] [Related]
11. Risk Factors of Daunorubicine Induced Early Cardiotoxicity in Childhood Acute Lymphoblastic Leukemia: A Retrospective Study.
Samosir SM; Utamayasa IKA; Andarsini MR; Rahman MA; Ontoseno T; Hidayat T; Ugrasena IDG; Larasati MCS; Cahyadi A
Asian Pac J Cancer Prev; 2021 May; 22(5):1407-1412. PubMed ID: 34048168
[TBL] [Abstract][Full Text] [Related]
12. The value of echocardiography versus cardiac troponin I levels in the early detection of anthracycline cardiotoxicity in childhood acute leukemia: prospective evaluation of a 7-year-long clinical follow-up.
Oztarhan K; Guler S; Aktas B; Arslan M; Salcioglu Z; Aydogan G
Pediatr Hematol Oncol; 2011 Aug; 28(5):380-94. PubMed ID: 21699467
[TBL] [Abstract][Full Text] [Related]
13. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia.
Lipshultz SE; Lipsitz SR; Sallan SE; Dalton VM; Mone SM; Gelber RD; Colan SD
J Clin Oncol; 2005 Apr; 23(12):2629-36. PubMed ID: 15837978
[TBL] [Abstract][Full Text] [Related]
14. Prospective longitudinal assessment of late anthracycline cardiotoxicity after childhood cancer: the role of diastolic function.
Dorup I; Levitt G; Sullivan I; Sorensen K
Heart; 2004 Oct; 90(10):1214-6. PubMed ID: 15367528
[No Abstract] [Full Text] [Related]
15. Low anthracyclines doses-induced cardiotoxicity in acute lymphoblastic leukemia long-term female survivors.
Amigoni M; Giannattasio C; Fraschini D; Galbiati M; Capra AC; Madotto F; Cesana F; Jankovic M; Masera G; Mancia G
Pediatr Blood Cancer; 2010 Dec; 55(7):1343-7. PubMed ID: 20589666
[TBL] [Abstract][Full Text] [Related]
16. Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer.
Feijen EA; Leisenring WM; Stratton KL; Ness KK; van der Pal HJ; Caron HN; Armstrong GT; Green DM; Hudson MM; Oeffinger KC; Robison LL; Stovall M; Kremer LC; Chow EJ
J Clin Oncol; 2015 Nov; 33(32):3774-80. PubMed ID: 26304888
[TBL] [Abstract][Full Text] [Related]
17. New insight into the intraventricular pressure gradient as a sensitive indicator of diastolic cardiac dysfunction in patients with childhood cancer after anthracycline therapy.
Shigemitsu S; Takahashi K; Yazaki K; Kobayashi M; Yamada M; Akimoto K; Tamaichi H; Fujimura J; Saito M; Nii M; Itatani K; Shimizu T
Heart Vessels; 2019 Jun; 34(6):992-1001. PubMed ID: 30673819
[TBL] [Abstract][Full Text] [Related]
18. Long-term cardiac follow-up of children treated with anthracycline doses of 300 mg/m2 or less for acute lymphoblastic leukemia.
Rathe M; Carlsen NL; Oxhøj H; Nielsen G
Pediatr Blood Cancer; 2010 Mar; 54(3):444-8. PubMed ID: 19830828
[TBL] [Abstract][Full Text] [Related]
19. [Echocardiography studies for detection of cardiotoxic side effects of anthracycline therapy in childhood].
Richter R; Grumpelt U; Mittler U; Kluba U
Monatsschr Kinderheilkd; 1990 Dec; 138(12):823-7. PubMed ID: 1965011
[TBL] [Abstract][Full Text] [Related]
20. Multicentre analysis of anthracycline-induced cardiotoxicity in children following treatment according to the nephroblastoma studies SIOP No.9/GPOH and SIOP 93-01/GPOH.
Marx M; Langer T; Graf N; Hausdorf G; Stöhr W; Ludwig R; Beck JD
Med Pediatr Oncol; 2002 Jul; 39(1):18-24. PubMed ID: 12116074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
